Spinneret - Weaving the chemical web one molecule at a time...

The US Food and Drug Administration (FDA) has approved Tysabri (Natalizumab), a monoclonal antibody for the treatment of moderate to severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies. So reports MediceNews.net.

More on this story about the Crohn’s disease drug approval here.

Molecules | Comments Off

Sufferers of irritable bowel syndrome (IBS) apparently have more protein receptors for the active compounds in chilli peppers, according to a study to be published June 11 in the journal Gut (PDF). The findings might one day lead to new treatments for IBS.

A chilli gut feeling about IBS.

Molecules | Comments Off